IP Library › Granted Patent US 11,913,042
Granted Patent B2
US 11,913,042 · App. 16/771,700 · Granted Feb 27, 2024

Methods for preparing and using highly active blood coagulation factor XI mutant and gene therapy/editing vector and recombinant/fusion protein thereof

Inventors: Xuefeng Wang (Shanghai, CN); Wenman Wu (Shanghai, CN); Qiulan Ding (Shanghai, CN)
Assignees: RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE; Wenman Wu; Xuefeng Wang; Qiulan Ding
C12N9/6443A61K48/005A61P7/04C12N15/85C12Y304/21027A61K38/00C12N2800/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,913,042
App. No.
16/771,700
Granted
Feb 27, 2024
Kind
B2
Abstract

Methods of preparing and using a highly active blood coagulation factor XI mutant and a gene therapy/editing vector thereof and a recombinant/fusion protein thereof. The nucleotide sequence of the mutant is as shown in SEQ ID NOs: 1-6, and the amino acid sequence is as shown in SEQ ID NO: 7.

Claims (15)

1. A highly active blood coagulation factor XI nucleic acid, comprising:

(1) the nucleotide sequence thereof is as shown in SEQ ID NO: 1, the nucleotide at position 1189 is A rather than G; or

(2) the nucleotide sequence thereof is as shown in SEQ ID NO: 2, the nucleotide at position 1189 is A rather than G, and the nucleotide at position 1191 is C rather than T; or

(3) the nucleotide sequence thereof is as shown in SEQ ID NO: 3, the nucleotide at position 1189 is T rather than G, and the nucleotide at position 1190 is C rather than G; or

(4) the nucleotide sequence thereof is as shown in SEQ ID NO: 4, the nucleotide at position 1189 is T rather than G, the nucleotide at position 1190 is C rather than G, and the nucleotide at position 1191 is C rather than T; or

(5) the nucleotide sequence thereof is as shown in SEQ ID NO: 5, the nucleotide at position 1189 is T rather than G, the nucleotide at position 1190 is C rather than G, and the nucleotide at position 1191 is A rather than T; or

(6) the nucleotide sequence thereof is as shown in SEQ ID NO: 6, the nucleotide at position 1189 is T rather than G, the nucleotide at position 1190 is C rather than G, and the nucleotide at position 1191 is G rather than T.

2. A highly active blood coagulation factor XI protein according to claim 1 , wherein the amino acid sequence thereof is as shown in SEQ ID NO: 7, the amino acid at position 397 in the mutant (FXI G397S) is Ser rather than Gly in human wild-type FXI (hFXI).

3. A nucleic acid encoding the highly active blood coagulation factor XI protein according to claim 2 , or a nucleic acid having the same length as and being completely complementary to the encoding nucleic acid.

4. A vector expressing the highly active blood coagulation factor XI protein according to claim 2 .

5. A method for preparing a highly active blood coagulation factor XI protein, comprising the steps of:

(1) inserting a human coagulation factor XI gene of human blood coagulation factor XI Gly397Ser mutant into a vector to obtain a recombinant vector;

(2) transforming a host cell with the above recombinant vector to obtain a cell clone expressing the recombinant blood coagulation factor XI Gly397Ser mutant;

(3) cultivating the above recombinant cell clone in a serum-free medium by continuous perfusion to induce expression of the recombinant blood coagulation factor XI Gly397Ser mutant protein;

(4) performing isolation, purification, filtration, final filling and lyophilization to obtain the expressed highly active blood coagulation factor XI Gly397Ser mutant protein, wherein the position of the mutation is relative to the wild type human factor XI sequence of SEQ ID NO: 8.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2020
From: WANG, XUEFENG; WU, WENMAN; DING, QIULAN
To: RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE; WANG, XUEFENG; WU, WENMAN; DING, QIULAN
Reel/Frame 052983/0650 →
Priority Claims (1)
CN 201711310506.2 · Dec 11, 2017 · national
Continuity (1)
Related Publication 20210207115A1 · Jul 8, 2021